Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A machine learning signature study with in vitro validation of a candidate gene, but lacking prospective clinical validation, hard clinical endpoints, or therapeutic trial data to support clinical implementation.
A single-centre, mechanistic study identifying a gene target for β-cell transdifferentiation with proof-of-concept in primary human cells and mouse transplantation, but lacking human clinical data and requiring confirmation in larger systems.
Early-phase in vitro and xenograft study showing proof-of-concept for a three-drug combination in KRAS G12C NSCLC cells; mechanistic finding without human clinical data or toxicology beyond weight observation.
A sound but single-cancer-model mechanistic study with cell-line and xenograft data, identifying a druggable autophagy-CMA pathway in KRAS-mutant pancreatic cancer; needs confirmation in clinical trials.
This is a narrative review synthesizing mechanistic understanding of how cancer cells exploit UPR signaling; it raises questions about therapeutic opportunity rather than testing efficacy in a clinical or experimental design.
Mechanistic, exploratory study identifying a candidate gene target through bioinformatic screening and uncontrolled in vitro experiments without clinical validation or efficacy data in human disease.
Early-stage mechanistic discovery in model organisms and cultured cells identifying a candidate compound and signaling pathway, without in vivo efficacy data or clinical translation.